Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for ORKA-001 in Psoriasis. The expected timing is based on the latest available company guidance and may change.
EVERLAST-A Phase 2a trial. 7/21/25- Received IND clearance. 8/11/25- Dosed first patient w/ data in H2 2026. 9/17/25- Ph1 interim results presented at EADV. 11/12/25:- Ph1 interim EADV data favorable. EVERLAST-A enrolling well; Week16 and duration data in H2 2026. EVERLAST-B starts H1 2026. 03/12/26:- EVERLAST-A enrollment completed; Week16 data expected Q2 2026, longer-term data in H2 2026. 04/27/26:- EVERLAST-A Ph2a Week16 PASI100 63.5%. Longer-term Week28/52wk data expected H2 2026. 05/13/26:- EVERLAST-A Week16 PASI100 63.5%, PASI90 83%, IGA0/1 84%; annual dosing PK; longer-term data H2 2026. 08/10/26:- EVERLAST-A Week28 data expected end Q3 2026. Week52 data expected December 2026. Phase3 starts H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.